Nils Lonberg

USPTO Granted Patents = 66 (Patent Applications = 34)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 17 (Patent Applications = 23)

Average Co-Inventor Count = 3.6

ph-index = 25

Forward Citations = 12,656(Granted Patents)

Forward Citations (Not Self Cited) = 12,343(Oct 12, 2025)

Inventors with similar research interests:

Location History:

San Francisco, CA (US) (1996 - 1999)
Redwood City, CA (US) (1997 - 2012)
Woodside, CA (US) (2001 - 2024)

Company Filing History:

25 out of 3,681

Bristol-myers Squibb Compnay

patents

17 out of 28

Genpharm International, Inc.

E. R. Squibb Sons, Inc.

patents

5. 5 out of 272

Kyowa Hakko Kirin Co., Limited

Five Prime Therapeutics, Inc.

patents

9. 2 out of 531

University of Cincinnati

patents

10. 1 out of 42

Kirin Brewery Company, Limited

patents

11. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

66 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12435136 - Antibodies binding to ILT4 (2025-10-07),

2. 12173081 - CD19/CD38 multispecific antibodies (2024-12-24),

3. 12049503 - Treatment of LAG-3 positive tumors (2024-07-30),

4. 11807686 - Treatment of LAG-3 positive tumors (2023-11-07),

5. 11802162 - Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof (2023-10-31),

6. 11723975 - Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody (2023-08-15),

7. 11408889 - Anti-GITR antibodies for cancer diagnostics (2022-08-09),

8. 11401328 - Antibodies binding to ILT4 (2022-08-02),

9. 11384363 - HCO32 and HCO27 and related examples (2022-07-12),

10. 11352440 - Antibodies against CD73 and uses thereof (2022-06-07),

11. 11345752 - Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-05-31),

12. 11299551 - Composite binding molecules targeting immunosuppressive B cells (2022-04-12),

13. 11274152 - Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors (2022-03-15),

14. 11213586 - Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) (2022-01-04),

15. 11084881 - Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof (2021-08-10),

Title: The Innovative Journey of Nils Lonberg

Introduction: Nils Lonberg, a pioneering inventor based in Woodside, CA (US), has made significant contributions to the field of biotechnology through his groundbreaking innovations.

Latest Patents: Nils Lonberg holds several patents in the biotechnology sector, focusing on novel methods for drug development and targeted therapies.

Career Highlights: With a distinguished career spanning over two decades, Nils Lonberg has worked with leading research institutions and biopharmaceutical companies to advance the frontiers of biotechnology.

Collaborations: Throughout his career, Nils Lonberg has collaborated with top scientists, researchers, and industry experts to bring cutting-edge inventions to life, revolutionizing the field of biotechnology.

Conclusion: Nils Lonberg's relentless pursuit of innovation and his commitment to pushing the boundaries of biotechnology make him a true visionary in the world of inventors.

This text is generated by artificial intelligence and may not be accurate.